CA2601289A1 - Once-a-day oxycodone formulations - Google Patents
Once-a-day oxycodone formulations Download PDFInfo
- Publication number
- CA2601289A1 CA2601289A1 CA002601289A CA2601289A CA2601289A1 CA 2601289 A1 CA2601289 A1 CA 2601289A1 CA 002601289 A CA002601289 A CA 002601289A CA 2601289 A CA2601289 A CA 2601289A CA 2601289 A1 CA2601289 A1 CA 2601289A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- hours
- patients
- oxycodone
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Abstract
The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/C max oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
Claims (18)
1. A sustained-release oral dosage form for once-a-day administration comprising:
a pharmaceutically acceptable matrix comprising an analgesically effective amount of oxycodone or a pharmaceutically acceptable salt thereof and a sustained release material, said dosage form providing an analgesic effect for at least about 24 hours after oral administration at steady state to human patients; and said dosage form providing a mean C24/C max oxycodone ratio of 0.6 to 1.0 after steady state oral administration to said patients.
a pharmaceutically acceptable matrix comprising an analgesically effective amount of oxycodone or a pharmaceutically acceptable salt thereof and a sustained release material, said dosage form providing an analgesic effect for at least about 24 hours after oral administration at steady state to human patients; and said dosage form providing a mean C24/C max oxycodone ratio of 0.6 to 1.0 after steady state oral administration to said patients.
2. The dosage form of claim 1, which provides a mean T max of oxycodone at about 2 to about 17 hours after administration at steady state to said patients.
3. The dosage form of claim 1, which provides a mean T max of oxycodone at about 8 to about 16 hours after administration at steady state to said patients.
4. The dosage form of claim 1, wherein the matrix is substantially homogeneous.
5. The dosage form of claim 1, wherein said matrix is contained within a gelatin capsule.
6. The dosage form of claim 1, wherein said matrix is formulated into a tablet.
7. The dosage form of claim 1, which provides a mean T max at about 12 to about 16 hours after administration at steady state to said patients.
8. The dosage form of claim 1, wherein said oxycodone or pharmaceutically acceptable salt thereof is an amount from about 5 to about 640 mg.
9. The dosage form of claim 1, wherein said pharmaceutically acceptable salt of oxycodone is oxycodone hydrochloride.
10. The dosage form of claim 1, which provides a mean C24/C max ratio of 0.7 to 0.99 after administration at steady state to said patients.
11. The dosage form of claim 1, which provides a mean C24/C max ratio of 0.8 to 0.95 after administration at steady state to said patients.
12. The dosage form of claim 1, which provides an in-vitro release rate, of oxycodone or a pharmaceutically acceptable salt thereof, when measured by the USP Basket Method at 100 rpm in 900 ml aqueous buffer at a pH of between 1.6 and 7.2 at 37°C of from 0% to about 40% at 1 hour, from about 8% to about 70% at 4 hours, from about 20% to about 80% at 8 hours, from about 30% to about 95% at 12 hours, from about 35% to about 95% at 18 hrs, and greater than about 50% at 24 hours.
13. A method of treating pain in patients comprising:
orally administering to human patients on a once a day basis, a sustained release dosage form comprising a pharmaceutically acceptable matrix comprising oxycodone or a pharmaceutically acceptable salt thereof and a sustained release material, to provide an analgesic effect for at least about 24 hours and a mean C24/C max oxycodone ratio of 0.6 to 1.0 after administration at steady state to said patients.
orally administering to human patients on a once a day basis, a sustained release dosage form comprising a pharmaceutically acceptable matrix comprising oxycodone or a pharmaceutically acceptable salt thereof and a sustained release material, to provide an analgesic effect for at least about 24 hours and a mean C24/C max oxycodone ratio of 0.6 to 1.0 after administration at steady state to said patients.
14. The method of claim 13 which provides a mean T max of oxycodone at about 2 to about 17 hours after administration at steady state to said patients.
15. The method of claim 13, which provides a mean T max of oxycodone at about 8 to about 16 hours after administration at steady state to said patients.
16. The method of claim 13, which provides a mean C24/C max ratio of 0.7 to 0.99 after administration at steady state to said patients.
17. The method of claim 13, which provides a mean C24/C max ratio of 0.8 to 0.95 after administration at steady state to said patients.
18. The method of claim 13, wherein said dosage form provides an in-vitro release rate, of oxycodone or a pharmaceutically acceptable salt thereof, when measured by the USP
Basket Method at 100 rpm in 900 ml aqueous buffer at a pH of between 1.6 and 7.2 at 37°C
of from 0% to about 40% at 1 hour, from about 8% to about 70% at 4 hours, from about 20%
to about 80% at 8 hours, from about 30% to about 95% at 12 hours, from about 35% to about 95% at 18 hrs, and greater than about 50% at 24 hours.
Basket Method at 100 rpm in 900 ml aqueous buffer at a pH of between 1.6 and 7.2 at 37°C
of from 0% to about 40% at 1 hour, from about 8% to about 70% at 4 hours, from about 20%
to about 80% at 8 hours, from about 30% to about 95% at 12 hours, from about 35% to about 95% at 18 hrs, and greater than about 50% at 24 hours.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28821101P | 2001-05-02 | 2001-05-02 | |
US60/288,211 | 2001-05-02 | ||
CA002474904A CA2474904C (en) | 2001-05-02 | 2002-05-02 | Once-a-day oxycodone formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002474904A Division CA2474904C (en) | 2001-05-02 | 2002-05-02 | Once-a-day oxycodone formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2601289A1 true CA2601289A1 (en) | 2002-11-07 |
CA2601289C CA2601289C (en) | 2011-04-19 |
Family
ID=23106212
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2601289A Expired - Fee Related CA2601289C (en) | 2001-05-02 | 2002-05-02 | Once-a-day oxycodone formulations |
CA2601222A Expired - Fee Related CA2601222C (en) | 2001-05-02 | 2002-05-02 | Once-a-day oxycodone formulations |
CA002474904A Expired - Fee Related CA2474904C (en) | 2001-05-02 | 2002-05-02 | Once-a-day oxycodone formulations |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2601222A Expired - Fee Related CA2601222C (en) | 2001-05-02 | 2002-05-02 | Once-a-day oxycodone formulations |
CA002474904A Expired - Fee Related CA2474904C (en) | 2001-05-02 | 2002-05-02 | Once-a-day oxycodone formulations |
Country Status (30)
Country | Link |
---|---|
US (1) | US7846476B2 (en) |
EP (5) | EP2281555B1 (en) |
JP (5) | JP4656815B2 (en) |
KR (9) | KR101366399B1 (en) |
CN (2) | CN101627974B (en) |
AU (1) | AU2002303614B2 (en) |
CA (3) | CA2601289C (en) |
CZ (2) | CZ305211B6 (en) |
DK (3) | DK1416921T3 (en) |
EA (1) | EA005627B1 (en) |
ES (3) | ES2530719T3 (en) |
HK (3) | HK1065482A1 (en) |
HR (2) | HRP20030951B1 (en) |
HU (1) | HUP0401601A3 (en) |
IL (5) | IL158723A0 (en) |
IS (1) | IS7011A (en) |
MA (1) | MA27128A1 (en) |
ME (1) | ME00330B (en) |
MX (1) | MXPA03010079A (en) |
NO (3) | NO337039B1 (en) |
NZ (3) | NZ576494A (en) |
PL (2) | PL368901A1 (en) |
PT (2) | PT1416921E (en) |
RS (3) | RS20120514A3 (en) |
SI (3) | SI2011485T1 (en) |
SK (2) | SK288220B6 (en) |
TN (1) | TNSN03108A1 (en) |
UA (3) | UA81224C2 (en) |
WO (1) | WO2002087512A2 (en) |
ZA (1) | ZA200308599B (en) |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU773642C (en) | 1997-12-22 | 2006-04-06 | Mundipharma Pty Limited | Opioid agonist/antagonist combinations |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
KR101216270B1 (en) | 1999-10-29 | 2012-12-31 | 유로-셀티크 소시에떼 아노뉨 | Controlled release hydrocodone formulations |
CA2427815C (en) | 2000-10-30 | 2007-07-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
CA2446550C (en) | 2001-05-11 | 2012-03-06 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
CN102813654A (en) | 2002-04-05 | 2012-12-12 | 欧洲凯尔蒂克公司 | Matrix for sustained, invariant and independent release of active compounds |
ES2320435T3 (en) * | 2002-04-29 | 2009-05-22 | Alza Corporation | METHOD AND DOSAGE FORMS FOR THE CONTROLLED ADMINISTRATION OF OXICODONE. |
US20050106249A1 (en) * | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
EP1513497A2 (en) * | 2002-05-31 | 2005-03-16 | Alza Corporation | Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US8840928B2 (en) | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US20050208132A1 (en) * | 2002-07-29 | 2005-09-22 | Gayatri Sathyan | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
ES2553136T3 (en) | 2002-12-13 | 2015-12-04 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid vehicle materials |
DE602004031096D1 (en) | 2003-03-26 | 2011-03-03 | Egalet As | MORPHINE SYSTEM WITH CONTROLLED RELEASE |
US20060165790A1 (en) * | 2003-06-27 | 2006-07-27 | Malcolm Walden | Multiparticulates |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE10361596A1 (en) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
EP1708684A2 (en) | 2003-09-26 | 2006-10-11 | Alza Corporation | Drug coating providing high drug loading and methods for providing the same |
ATE504288T1 (en) * | 2003-09-26 | 2011-04-15 | Alza Corp | OROS PUSH STICK FOR THE CONTROLLED DELIVERY OF ACTIVE INGREDIENTS |
KR20060108690A (en) * | 2003-10-29 | 2006-10-18 | 알자 코포레이션 | Once-a-day, oral, controlled-release, oxycodone dosage forms |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
TWI483944B (en) | 2004-03-30 | 2015-05-11 | Euro Celtique Sa | Oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oral dosage form,and pharmaceutically acceptable package having less than 25 ppm 14-hydroxycodeinone |
EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
KR20070048272A (en) | 2004-09-01 | 2007-05-08 | 유로-셀띠끄 소시에떼 아노님 | Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax |
WO2006030402A2 (en) * | 2004-09-17 | 2006-03-23 | Ranbaxy Laboratories Limited | Dual compartment osmotic delivery device |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
WO2006046114A2 (en) * | 2004-10-25 | 2006-05-04 | Ranbaxy Laboratories Limited | Osmotic dosage forms providing ascending drug release, and processes for their preparation |
TWI432196B (en) * | 2005-01-18 | 2014-04-01 | Euro Celtique Sa | Method of treating visceral pain |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
MX2007012220A (en) * | 2005-04-06 | 2007-12-06 | Mallinckrodt Inc | Matrix-based pulse release pharmaceutical formulation. |
DE102005048293A1 (en) * | 2005-10-08 | 2007-04-12 | Sanofi-Aventis Deutschland Gmbh | Retard formulation for pralnacasan |
ZA200807571B (en) * | 2006-03-01 | 2009-08-26 | Ethypharm Sa | Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
ES2524556T3 (en) | 2006-10-09 | 2014-12-10 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
AU2008335809A1 (en) | 2007-12-06 | 2009-06-18 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition |
EP3090743A1 (en) | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CA2720108C (en) | 2008-03-11 | 2016-06-07 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
SI2405915T1 (en) | 2009-03-10 | 2019-03-29 | Euro-Celtique S.A. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
WO2010149169A2 (en) | 2009-06-24 | 2010-12-29 | Egalet A/S | Controlled release formulations |
CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
BR112012001547A2 (en) | 2009-07-22 | 2016-03-08 | Gruenenthal Gmbh | hot melt extruded pharmaceutical dosage form |
JP2012533585A (en) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant dosage forms for oxidation-sensitive opioids |
IT1395143B1 (en) * | 2009-08-06 | 2012-09-05 | Sofar Spa | GRANULAR COMPOSITIONS WITH CONTROLLED RELEASE OF MESALAZINE AND PROCESS FOR THEIR ACHIEVEMENT. |
EP3064064A1 (en) | 2009-09-30 | 2016-09-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
WO2011143120A1 (en) | 2010-05-11 | 2011-11-17 | Cima Labs Inc. | Alcoholres i stant metoprolol - containing extended - release oral dosage forms |
WO2012028319A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
JP2013537915A (en) * | 2010-09-24 | 2013-10-07 | キューアールエックスファーマ リミテッド | Opioid controlled release formulations |
KR200453833Y1 (en) * | 2010-10-18 | 2011-05-27 | 잘만테크 주식회사 | Cooling fan |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
PL2726064T3 (en) * | 2011-06-30 | 2017-06-30 | Develco Pharma Schweiz Ag | Controlled release oral dosage form comprising oxycodone |
CN103857386A (en) | 2011-07-29 | 2014-06-11 | 格吕伦塔尔有限公司 | Tamper-resistant tablet providing immediate drug release |
BR112014002022A2 (en) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | tamper-resistant tablet providing immediate drug release |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
AU2013248351B2 (en) | 2012-04-18 | 2018-04-26 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
SG11201407300VA (en) | 2012-05-07 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of neurological disorders |
AU2013257742A1 (en) | 2012-05-07 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
EP2852569B1 (en) | 2012-05-23 | 2020-10-14 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
CN104603100A (en) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | Compositions and methods for treatment of inflammatory bowel disease |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
KR20150059167A (en) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | Abuse deterrent pharmaceutical compositions for controlled release |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
CN104364231A (en) | 2012-09-08 | 2015-02-18 | 塞利克斯比奥私人有限公司 | Compositions and methods for treatment of inflammation and lipid disorders |
MX366159B (en) | 2012-11-30 | 2019-07-01 | Acura Pharmaceuticals Inc | Self-regulated release of active pharmaceutical ingredient. |
CN105120659A (en) | 2013-03-15 | 2015-12-02 | 度瑞公司 | Compositions with a rheological modifier to reduce dissolution variability |
CN104042581B (en) * | 2013-03-15 | 2016-10-19 | 中国药科大学 | Oxycodone hydrochloride sustained-release preparation and preparation method thereof |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
BR112015026549A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-proof dosage form containing one or more particles |
AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
JP2016525138A (en) | 2013-07-23 | 2016-08-22 | ユーロ−セルティーク エス.エイ. | Oxycodone and naloxone combination for use in the treatment of pain in patients suffering from diseases that cause pain and intestinal dysbiosis and / or diseases that increase the risk for intestinal bacterial transfer |
JP6539274B2 (en) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | Extruded immediate release abuse deterrent pills |
US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
MX2016014738A (en) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol. |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
ES2809458T3 (en) | 2014-07-17 | 2021-03-04 | Pharmaceutical Manufacturing Res Services Inc | Liquid filled, abuse deterrent and immediate release dosage form |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
SG11201702554QA (en) | 2014-09-29 | 2017-04-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
WO2016098119A1 (en) | 2014-10-27 | 2016-06-23 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
CA2973178C (en) | 2015-01-06 | 2022-11-01 | Cellix Bio Private Limited | Bupivacaine derivatives and their use in the treatment of inflammation and pain |
AU2016251854A1 (en) | 2015-04-24 | 2017-10-19 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
JP2018526414A (en) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Protection against oral overdose with abuse-inhibiting immediate release formulations |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
JP2019507181A (en) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (173)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA635283A (en) | 1962-01-23 | Olin Mathieson Chemical Corporation | Pellets for prolonged drug action | |
US2738303A (en) * | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
US2921883A (en) * | 1957-05-03 | 1960-01-19 | Smith Kline French Lab | Novel coating material for medicaments |
NL263733A (en) * | 1960-04-19 | 1900-01-01 | ||
US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (en) | 1960-11-29 | |||
US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US4132753A (en) * | 1965-02-12 | 1979-01-02 | American Cyanamid Company | Process for preparing oral sustained release granules |
US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
NL6714885A (en) | 1967-11-02 | 1969-05-06 | ||
US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3634584A (en) * | 1969-02-13 | 1972-01-11 | American Home Prod | Sustained action dosage form |
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US3773920A (en) | 1971-07-14 | 1973-11-20 | Nikken Chemicals Co Ltd | Sustained release medicinal composition |
US3965256A (en) * | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3922339A (en) | 1974-06-20 | 1975-11-25 | Kv Pharm Co | Sustained release medicant |
GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4036228A (en) | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4111201A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
JPS5535031A (en) * | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
IE48715B1 (en) * | 1978-12-22 | 1985-05-01 | Elan Corp Plc | New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same |
FI63335B (en) * | 1979-02-02 | 1983-02-28 | Orion Yhtymae Oy | FARING REFERENCE FOR A TABLETTER WITH A LIGHT LIGHT OF AN EFFECTIVE |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
DE3126703A1 (en) * | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | BROMHEXIN RETARD FORM AND METHOD FOR THEIR PRODUCTION |
US4377568A (en) * | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
DE3208791A1 (en) * | 1982-03-11 | 1983-09-22 | Röhm GmbH, 6100 Darmstadt | METHOD FOR COATING MEDICINAL PRODUCTS BY MEANS OF A COATING AGENT DISPERSED IN WATER |
US4455143A (en) * | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
AU1873783A (en) | 1982-10-08 | 1984-04-12 | Verex Laboratories Inc. | Constant release formulation |
US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
EP0147780A3 (en) | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Drug delivery device |
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US4894234A (en) * | 1984-10-05 | 1990-01-16 | Sharma Shri C | Novel drug delivery system for antiarrhythmics |
JPS61152765A (en) * | 1984-12-27 | 1986-07-11 | Nippon Ekishiyou Kk | Synthetic resin product including compound clathrated with cyclodextrin |
US4600645A (en) * | 1985-01-31 | 1986-07-15 | Warner-Lambert Company | Process for treating dosage forms |
GB2170104A (en) | 1985-01-30 | 1986-07-30 | Warner Lambert Co | Coated pharmaceutical dosage forms |
US4772475A (en) | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
NL8500724A (en) | 1985-03-13 | 1986-10-01 | Univ Groningen | DEVICES FOR REGULAR RELEASE OF ACTIVE SUBSTANCES AND METHOD OF MANUFACTURE THEREOF |
ATE84713T1 (en) * | 1985-05-13 | 1993-02-15 | Miles Inc | USE OF CALCIUM ANTAGONISTS TO PREPARING COMPOSITIONS FOR WITHDRAWAL SYMPTOMS. |
GB8519310D0 (en) | 1985-07-31 | 1985-09-04 | Zyma Sa | Granular active substances |
GB8521350D0 (en) * | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
GB2186485B (en) | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
EP0249347B1 (en) * | 1986-06-10 | 1994-06-29 | Euroceltique S.A. | Controlled release dihydrocodeine composition |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4760094A (en) | 1986-10-21 | 1988-07-26 | American Home Products Corporation (Del.) | Spray dried acetaminophen |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
US5219575A (en) * | 1987-06-26 | 1993-06-15 | Duphar International Research B.V. | Compositions with controlled zero-order delivery rate and method of preparing these compositions |
DE3721721C1 (en) * | 1987-07-01 | 1988-06-09 | Hoechst Ag | Process for coating granules |
US5068110A (en) | 1987-09-29 | 1991-11-26 | Warner-Lambert Company | Stabilization of enteric coated dosage form |
EP0327295A3 (en) | 1988-02-01 | 1989-09-06 | F.H. FAULDING & CO. LTD. | Tetracycline dosage form |
DE3812567A1 (en) | 1988-04-15 | 1989-10-26 | Basf Ag | METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES |
US5019397A (en) * | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
US5024842A (en) * | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
JP2681373B2 (en) * | 1988-07-18 | 1997-11-26 | 塩野義製薬株式会社 | Method for manufacturing sustained-release preparation |
JP2850376B2 (en) * | 1988-08-02 | 1999-01-27 | 日産化学工業株式会社 | Anticancer drug efficacy enhancer |
GB8820327D0 (en) | 1988-08-26 | 1988-09-28 | May & Baker Ltd | New compositions of matter |
US4983730A (en) * | 1988-09-02 | 1991-01-08 | Hoechst Celanese Corporation | Water soluble cellulose acetate composition having improved processability and tensile properties |
DE68916497T2 (en) | 1988-09-30 | 1994-11-17 | Rhone Poulenc Rorer Ltd | Pharmaceutical granules. |
US5178868A (en) * | 1988-10-26 | 1993-01-12 | Kabi Pharmacia Aktiebolaq | Dosage form |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5330766A (en) * | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
CA2007181C (en) | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
CA2007055A1 (en) | 1989-01-06 | 1990-07-06 | Garth Boehm | Theophylline dosage form |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5196203A (en) * | 1989-01-06 | 1993-03-23 | F. H. Faulding & Co. Limited | Theophylline dosage form |
US5326572A (en) | 1989-03-23 | 1994-07-05 | Fmc Corporation | Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5122384A (en) * | 1989-05-05 | 1992-06-16 | Kv Pharmaceutical Company | Oral once-per-day organic nitrate formulation which does not induce tolerance |
FR2648020B1 (en) * | 1989-06-12 | 1992-03-13 | Rhone Poulenc Sante | USE OF COMPOSITIONS DEGRADABLY BY ENZYMATICS FOR THE COATING OF FOOD ADDITIVES FOR RUMINANTS |
DK161743C (en) * | 1989-07-03 | 1992-02-17 | Niro Atomizer As | PROCEDURE AND APPARATUS FOR AGGLOMERATION OF A POWDER-SHAPED MATERIAL |
DE415693T1 (en) | 1989-08-28 | 1991-10-17 | Arizona Technology Development Corp., Tucson, Ariz., Us | COMPOSITION AND METHOD FOR SELECTIVELY REINFORCING THE OPIATE EFFECT AND REDUCING OPIATE TOLERANCE AND DEPENDENCY. |
EP0418596A3 (en) * | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
IL96311A (en) | 1989-12-01 | 1995-05-26 | Abbott Lab | Sustained-release drug dosage units |
US5258436A (en) | 1989-12-19 | 1993-11-02 | Fmc Corporation | Film-forming composition; method of producing same and use for coating pharmaceuticals and foods and the like |
US5248516A (en) * | 1989-12-19 | 1993-09-28 | Fmc Corporation | Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like |
IE66933B1 (en) * | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
US5206030A (en) * | 1990-02-26 | 1993-04-27 | Fmc Corporation | Film-forming composition and use for coating pharmaceuticals, foods and the like |
JP3191948B2 (en) | 1990-04-12 | 2001-07-23 | 塩野義製薬株式会社 | Coated preparation and method for producing the same |
JP2542122B2 (en) * | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | Spherical nucleus, spherical granule and method for producing the same |
EP0472502B1 (en) * | 1990-08-24 | 1995-05-31 | Spirig Ag Pharmazeutische Präparate | Process for obtaining granules |
US5284662A (en) * | 1990-10-01 | 1994-02-08 | Ciba-Geigy Corp. | Oral osmotic system for slightly soluble active agents |
FR2669336B1 (en) | 1990-11-20 | 1993-01-22 | Adir | NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5132142A (en) * | 1991-03-19 | 1992-07-21 | Glatt Gmbh | Apparatus and method for producing pellets by layering power onto particles |
DK0580860T4 (en) * | 1991-04-16 | 2005-03-21 | Nippon Shinyaku Co Ltd | Process for preparing a solid dispersion |
KR100221695B1 (en) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | Pharmaceutical spheroid formulation |
DK0534628T3 (en) | 1991-09-06 | 1996-12-09 | Mcneilab Inc | Preparations containing a tramadol material and any one of codeine, oxycodone or hydrocodone, and use thereof |
US5215758A (en) * | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5223541A (en) | 1991-09-13 | 1993-06-29 | Mcneilab, Inc. | Tramadol n-oxide material, enantiomers and compositions thereof, and their use |
GB9121204D0 (en) | 1991-10-04 | 1991-11-20 | Euro Celtique Sa | Medicament |
AU661723B2 (en) | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
DE4138513A1 (en) | 1991-11-23 | 1993-05-27 | Basf Ag | SOLID PHARMACEUTICAL RETARD FORM |
US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
US5167964A (en) | 1992-02-14 | 1992-12-01 | Warner-Lambert Company | Semi-enteric drug delivery systems and methods for preparing same |
ATE404201T1 (en) | 1992-06-22 | 2008-08-15 | Univ California | GLYCINE RECEPTOR ANTAGONISTS AND THEIR USE |
SE9202250D0 (en) * | 1992-07-29 | 1992-07-29 | Gacell Lab Ab | CONTROLLED RELEASE MORPHINE PREPARATION |
US5324351A (en) | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
DE69332291T2 (en) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING WAX MATRICES |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
SE9301057L (en) * | 1993-03-30 | 1994-10-01 | Pharmacia Ab | Controlled release preparation |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
IL109944A (en) | 1993-07-01 | 1998-12-06 | Euro Celtique Sa | Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
DE4329794C2 (en) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadol salt-containing drugs with delayed release |
KR100354702B1 (en) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | Manufacturing method and sustained release composition of pharmaceutical composition |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US5475995A (en) | 1994-05-16 | 1995-12-19 | Livingston; George G. | Truck spare tire locking rod |
US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
US5460826A (en) * | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
US5529787A (en) * | 1994-07-07 | 1996-06-25 | Alza Corporation | Hydromorphone therapy |
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5811126A (en) * | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
DE69709646T2 (en) | 1996-03-12 | 2002-08-14 | Alza Corp | COMPOSITION AND DOSAGE WITH AN OPIOID ANTAGONIST |
WO1997045091A2 (en) * | 1996-05-31 | 1997-12-04 | Euro-Celtique, S.A. | Sustained release oxycodone formulations with no fed/fast effect |
US5948787A (en) * | 1997-02-28 | 1999-09-07 | Alza Corporation | Compositions containing opiate analgesics |
US5976579A (en) | 1997-07-03 | 1999-11-02 | Mclean; Linsey | Nutritional supplement for the prevention and treatment of excessive intestinal permeability |
US5959452A (en) * | 1997-10-03 | 1999-09-28 | The Johns Hopkins University | Lorentz force magnetometer having a resonator |
US6066339A (en) * | 1997-10-17 | 2000-05-23 | Elan Corporation, Plc | Oral morphine multiparticulate formulation |
US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
DE19901683B4 (en) * | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Controlled-release analgesic |
WO2001008661A2 (en) | 1999-07-29 | 2001-02-08 | Roxane Laboratories, Inc. | Opioid sustained-released formulation |
CA2427815C (en) * | 2000-10-30 | 2007-07-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
AU2002314968B2 (en) | 2001-06-08 | 2006-12-07 | Endo Pharmaceuticals, Inc. | Controlled release dosage forms using acrylic polymer, and process for making the same |
WO2003004032A1 (en) | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
US20050106249A1 (en) * | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
ES2320435T3 (en) * | 2002-04-29 | 2009-05-22 | Alza Corporation | METHOD AND DOSAGE FORMS FOR THE CONTROLLED ADMINISTRATION OF OXICODONE. |
EP1513497A2 (en) | 2002-05-31 | 2005-03-16 | Alza Corporation | Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
KR20060108690A (en) * | 2003-10-29 | 2006-10-18 | 알자 코포레이션 | Once-a-day, oral, controlled-release, oxycodone dosage forms |
-
2002
- 2002-02-05 UA UA20031210898A patent/UA81224C2/en unknown
- 2002-05-02 KR KR1020117009415A patent/KR101366399B1/en not_active IP Right Cessation
- 2002-05-02 EA EA200301165A patent/EA005627B1/en not_active IP Right Cessation
- 2002-05-02 PL PL02368901A patent/PL368901A1/en not_active Application Discontinuation
- 2002-05-02 EP EP10178548.3A patent/EP2281555B1/en not_active Expired - Lifetime
- 2002-05-02 SK SK5003-2008A patent/SK288220B6/en not_active IP Right Cessation
- 2002-05-02 WO PCT/US2002/014024 patent/WO2002087512A2/en active Application Filing
- 2002-05-02 ES ES08151238T patent/ES2530719T3/en not_active Expired - Lifetime
- 2002-05-02 MX MXPA03010079A patent/MXPA03010079A/en active IP Right Grant
- 2002-05-02 IL IL15872302A patent/IL158723A0/en unknown
- 2002-05-02 RS RS20120514A patent/RS20120514A3/en unknown
- 2002-05-02 KR KR1020127002850A patent/KR20120028993A/en not_active Application Discontinuation
- 2002-05-02 RS YU86003A patent/RS52577B/en unknown
- 2002-05-02 KR KR1020077005084A patent/KR20070030335A/en not_active Application Discontinuation
- 2002-05-02 NZ NZ576494A patent/NZ576494A/en not_active IP Right Cessation
- 2002-05-02 UA UAA200710400A patent/UA88056C2/en unknown
- 2002-05-02 HU HU0401601A patent/HUP0401601A3/en unknown
- 2002-05-02 ES ES10178548T patent/ES2571703T3/en not_active Expired - Lifetime
- 2002-05-02 KR KR1020037014225A patent/KR100656730B1/en not_active IP Right Cessation
- 2002-05-02 CA CA2601289A patent/CA2601289C/en not_active Expired - Fee Related
- 2002-05-02 SI SI200231052T patent/SI2011485T1/en unknown
- 2002-05-02 DK DK02731644.7T patent/DK1416921T3/en active
- 2002-05-02 CZ CZ2007-256A patent/CZ305211B6/en not_active IP Right Cessation
- 2002-05-02 SI SI200231049T patent/SI1416921T1/en unknown
- 2002-05-02 DK DK08151238.6T patent/DK2011485T3/en active
- 2002-05-02 JP JP2002584864A patent/JP4656815B2/en not_active Expired - Lifetime
- 2002-05-02 ME MEP-2008-493A patent/ME00330B/en unknown
- 2002-05-02 KR KR1020127034282A patent/KR20130018960A/en not_active Application Discontinuation
- 2002-05-02 EP EP10178549A patent/EP2269585A3/en not_active Withdrawn
- 2002-05-02 EP EP02731644.7A patent/EP1416921B1/en not_active Expired - Lifetime
- 2002-05-02 SI SI200231071A patent/SI2281555T1/en unknown
- 2002-05-02 PT PT2731644T patent/PT1416921E/en unknown
- 2002-05-02 CN CN200910148818.7A patent/CN101627974B/en not_active Expired - Fee Related
- 2002-05-02 KR KR1020097024943A patent/KR101043492B1/en not_active IP Right Cessation
- 2002-05-02 CZ CZ2003-3242A patent/CZ304442B6/en not_active IP Right Cessation
- 2002-05-02 US US10/476,409 patent/US7846476B2/en active Active
- 2002-05-02 KR KR1020137022168A patent/KR101476573B1/en not_active IP Right Cessation
- 2002-05-02 UA UAA200906438A patent/UA92115C2/en unknown
- 2002-05-02 EP EP16195554.7A patent/EP3146963A1/en not_active Withdrawn
- 2002-05-02 DK DK10178548.3T patent/DK2281555T3/en active
- 2002-05-02 EP EP08151238.6A patent/EP2011485B1/en not_active Revoked
- 2002-05-02 KR KR1020097006725A patent/KR20090037508A/en not_active Application Discontinuation
- 2002-05-02 CA CA2601222A patent/CA2601222C/en not_active Expired - Fee Related
- 2002-05-02 PT PT81512386T patent/PT2011485E/en unknown
- 2002-05-02 AU AU2002303614A patent/AU2002303614B2/en not_active Ceased
- 2002-05-02 KR KR1020067003432A patent/KR20060028821A/en active Search and Examination
- 2002-05-02 RS RS20110564A patent/RS56252B1/en unknown
- 2002-05-02 PL PL388076A patent/PL221881B1/en unknown
- 2002-05-02 CA CA002474904A patent/CA2474904C/en not_active Expired - Fee Related
- 2002-05-02 CN CNA028115597A patent/CN1514721A/en active Pending
- 2002-05-02 SK SK1462-2003A patent/SK288514B6/en not_active IP Right Cessation
- 2002-05-02 ES ES02731644.7T patent/ES2523145T3/en not_active Expired - Lifetime
- 2002-05-02 NZ NZ587010A patent/NZ587010A/en not_active IP Right Cessation
- 2002-05-02 NZ NZ529231A patent/NZ529231A/en not_active IP Right Cessation
-
2003
- 2003-07-08 TN TNPCT/US2002/014024A patent/TNSN03108A1/en unknown
- 2003-10-31 IS IS7011A patent/IS7011A/en unknown
- 2003-10-31 NO NO20034862A patent/NO337039B1/en not_active IP Right Cessation
- 2003-11-02 IL IL158723A patent/IL158723A/en not_active IP Right Cessation
- 2003-11-04 ZA ZA2003/08599A patent/ZA200308599B/en unknown
- 2003-11-21 HR HRP20030951AA patent/HRP20030951B1/en not_active IP Right Cessation
- 2003-12-02 MA MA27420A patent/MA27128A1/en unknown
-
2004
- 2004-10-25 HK HK04108354.9A patent/HK1065482A1/en not_active IP Right Cessation
- 2004-10-25 HK HK11107841.3A patent/HK1149722A1/en not_active IP Right Cessation
- 2004-10-25 HK HK09106074.7A patent/HK1128407A1/en not_active IP Right Cessation
-
2008
- 2008-11-14 JP JP2008291933A patent/JP5795138B2/en not_active Expired - Lifetime
-
2011
- 2011-03-08 IL IL211637A patent/IL211637A/en not_active IP Right Cessation
-
2012
- 2012-12-16 IL IL223673A patent/IL223673A/en not_active IP Right Cessation
-
2013
- 2013-01-30 NO NO20130159A patent/NO337963B1/en not_active IP Right Cessation
- 2013-06-04 JP JP2013117444A patent/JP5805707B2/en not_active Expired - Lifetime
-
2014
- 2014-10-01 HR HRP20140945AA patent/HRP20140945A2/en not_active Application Discontinuation
-
2015
- 2015-06-02 JP JP2015111923A patent/JP2015180669A/en not_active Withdrawn
-
2016
- 2016-05-06 NO NO20160765A patent/NO341144B1/en not_active IP Right Cessation
- 2016-09-22 IL IL247971A patent/IL247971A0/en unknown
-
2017
- 2017-02-24 JP JP2017033917A patent/JP2017114899A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2601289A1 (en) | Once-a-day oxycodone formulations | |
CA2126611A1 (en) | Opiod Formulations Having Extended Controlled Release | |
HUP0301591A2 (en) | Controlled release hydrocodone compositions | |
JP2005512995A5 (en) | ||
RU2003116058A (en) | COMPOSITIONS OF A HYDROCODON WITH CONTROLLED RELEASE | |
CA2389235A1 (en) | Controlled release hydrocodone formulations | |
US20070298098A1 (en) | Controlled Release Compositions Comprising Levetiracetam | |
RU2006106464A (en) | MEDICINAL FORMS WITH SLOW DELIVERY OF ZIPRAZIDONE | |
EP1595538A3 (en) | Modified release tamsulosin tablets | |
CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
JP2005528430A5 (en) | ||
RU2003100507A (en) | PHARMACEUTICAL COMPOSITIONS | |
CA2411882A1 (en) | Solid valsartan pharmaceutical compositions | |
JP3018160B2 (en) | Drug for reducing dysmenorrhea and / or premenstrual syndrome | |
CA2456604A1 (en) | Pharmaceutical composition comprising lumiracoxib | |
WO2006088864A1 (en) | Controlled release compositions comprising levetiracetam | |
CA2389032A1 (en) | Preventive or therapeutic agents for inflammatory diseases of intestine | |
CA2416771A1 (en) | 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders | |
WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
CA2386547C (en) | Orally disintegrating composition comprising mirtazapine | |
JPH05246845A (en) | Antipyretic analgesic agent containing ibuprofen | |
CA2746531C (en) | Non-steroidal anti-inflammatory drug dosage form | |
GB2282758A (en) | Oral morphine-6-glucuronide compositions | |
NZ207768A (en) | Sustained release tablets comprising dipyridamole | |
RS20060413A (en) | Non-disintegrating oral solid composition of high dose of water soluble drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220301 |
|
MKLA | Lapsed |
Effective date: 20200831 |